VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
Status:
Completed
Trial end date:
2006-11-27
Target enrollment:
Participant gender:
Summary
Eligible subjects will be randomized to receive VALTREX 1g or placebo once daily for 60 days
in a two-way crossover study with a washout period of 7 days in between.